Article Sidebar
Published:
Feb 13, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Chikusetsu saponin IVA induces apoptosis and mitochondrial dysfunction of benign prostatic hyperplasia epithelial cell line (BPH-1) by inhibiting JAK/STAT3 signaling pathway
Abstract
Purpose: To determine the potential effect of Chikusetsu saponin IVA (CS-IVA) on benign prostatic hyperplasia (BPH), as well as the mechanism of action.
Methods: Benign prostatic hyperplasia epithelial cell response to treatment by CS-IVA was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), colony formation assay, and cell cycle analysis. Flow cytometry and immunoblot assay were used to assess the effect of CS-IVA on cell apoptosis. Mitochondrial damage was examined by JC-1 staining and immunoblot, while immunoblot assay was also performed to determine the effect of CS-IVA on JAK/STAT3 pathway.
Results: CS-IVA inhibited the growth and cycle progression of BPH-1 cell but promoted cell apoptosis (p < 0.01). It also exacerbated mitochondrial damage in BPH-1 cell lines (p < 0.01). With regard to the mechanism of action, CS-IVA inhibited JAK/STAT3 pathway in BPH-1 cells (p < 0.01).
Conclusion: CS-IVA induces apoptosis and mitochondrial dysfunction of BPH-1 cells by inhibiting JAK/STAT3 pathway, and thus it is a potential drug for the treatment of BPH. However, in vivo studies on the effect of CS-IVA are are required to validate these results
